Breaking News

Statement by Assistant Secretary for Mine Safety and Health Williamson recognizing America’s mine workers on National Miners Day Wellesley Island Border Patrol Agents and the Jefferson County Sheriff’s Office Seized Approximately 150 Pounds of Marijuana FEMA Awards Almost $4.5 Million to Manchester-by-the-Sea to Fight Flooding Readout of Deputy Secretary of Defense Dr. Kathleen H. Hicks’ Meeting With U.K. Permanent Under Secretary of Defence David Williams News Release – VIDEO CONSUMER ALERT: Google Voice Identity Theft is On the Rise Remarks by Deputy Secretary of Commerce Don Graves at the NetZero World Industry Summit CSAF promotes retired WWII triple ace fighter pilot to brigadier general > Air Force > Article Display FDA Provides Update on External Evaluation to Strengthen Agency’s Human Foods Program

Issued: London UK

GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million. Ninety per cent of the share capital of MeiRui is to be acquired from Pagoda Pharmaceuticals Limited and the remaining ten per cent from Allergon AB in a move to further expand GSK’s presence in China, one of the fastest-growing and most significant of the emerging markets.

MeiRui is a leading Chinese pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome. GSK will gain access to this portfolio of products, as well as MeiRui’s established sales and marketing platform and a manufacturing facility in Nanjing City, Jiangsu Province, China.

Completion of the transaction is expected by the end of 2010, subject to regulatory approval.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

Nanjing Merui Pharmaceuticals (MeiRui) is a Chinese pharmaceutical company specializing in manufacturing urology and allergy medicines in China. MeiRui is the China operating entity of Pagoda Pharma Group Inc, a privately owned company registered in the British Virgin Islands.

GlaxoSmithKline Enquiries:

   

UK Media enquiries:

David Mawdsley
Claire Brough
Stephen Rea
Alexandra Harrison
Jo Revill

(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek
Mary Anne Rhyne
Kevin Colgan
Jennifer Armstrong

(919) 483 2839
(919) 483 2839
(919) 483 2839
(919) 483 2839

 

   

European Analyst/Investor enquiries:

Sally Ferguson
Gary Davies
Ziba Shamsi

(020) 8047 5543
(020) 8047 5503
(020) 8047 3289

     

US Analyst/ Investor enquiries:

Tom Curry
Jen Hill Baxter

(215) 751 5419
(215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2009.

Source link